N. Anthony Coles

Chairperson and Chief Executive Officer

Cerevel Therapeutics

TONY COLES is chairperson and chief executive officer of Cerevel Therapeutics, a biopharmaceutical company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. Dr. Coles is a founding investor and the chairman of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases. Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Dr. Coles was educated at Johns Hopkins University, earned a medical degree from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. In addition to his board roles at Cerevel and Yumanity, Dr. Coles currently serves on the board of directors of Regeneron (NASDAQ: REGN) and is a member of the board of trustees for Johns Hopkins University and Johns Hopkins Medicine. Dr. Coles is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; a member of the board of directors of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher; and a member on the Harvard Medical School Advisory Board. In 2021 Dr. Coles was elected to the American Academy of Arts and Sciences.